Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

Histamine inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer and T cells against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2). Two randomised phase II trials of IL-2 with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Donskov, F, Middleton, M, Fode, K, Meldgaard, P, Mansoor, W, Lawrance, J, Thatcher, N, Nellemann, H, von der Maase, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361635/
https://www.ncbi.nlm.nih.gov/pubmed/16136045
http://dx.doi.org/10.1038/sj.bjc.6602768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361635/
https://www.ncbi.nlm.nih.gov/pubmed/16136045
http://dx.doi.org/10.1038/sj.bjc.6602768

Ejemplares similares